Search Result

Results for "

DOTA-biotin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Apoptosis (1) Bacterial (2) BCL6 (1) Biochemical Assay Reagents (5) Bombesin Receptor (2) CCR (1) CGRP Receptor (1) Claudin (1) CXCR (2) Drug Derivative (1) EGFR (2) FAP (1) Fluorescent Dye (4) Gap Junction Protein (1) GCGR (1) Hapten (1) Integrin (1) Interleukin Related (2) Melanocortin Receptor (1) Neurokinin Receptor (1) Neuropeptide B/W Receptor (1) NF-κB (1) Proteasome (2) PSMA (2) Radionuclide-Drug Conjugates (RDCs) (12) Somatostatin Receptor (2) Src (1) Syk (1) Thyroid Hormone Receptor (1) Transmembrane Glycoprotein (2) VEGFR (1)
By Research Areas:	Cancer (24) Cardiovascular Disease (3) Endocrinology (1) Infection (2) Inflammation/Immunology (6) Metabolic Disease (1) Neurological Disease (8)

By Targets:

Amyloid-β (1)

Apoptosis (1)

Bacterial (2)

BCL6 (1)

Biochemical Assay Reagents (5)

Bombesin Receptor (2)

CCR (1)

CGRP Receptor (1)

Claudin (1)

CXCR (2)

Drug Derivative (1)

EGFR (2)

FAP (1)

Fluorescent Dye (4)

Gap Junction Protein (1)

GCGR (1)

Hapten (1)

Integrin (1)

Interleukin Related (2)

Melanocortin Receptor (1)

Neurokinin Receptor (1)

Neuropeptide B/W Receptor (1)

NF-κB (1)

Proteasome (2)

PSMA (2)

Radionuclide-Drug Conjugates (RDCs) (12)

Somatostatin Receptor (2)

Src (1)

Syk (1)

Thyroid Hormone Receptor (1)

Transmembrane Glycoprotein (2)

VEGFR (1)

By Research Areas:

Cancer (24)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (6)

Metabolic Disease (1)

Neurological Disease (8)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P11307

Biotin-epoxomicin	Proteasome	Cancer
Biotin-epoxomicin is a Proteasome subunit binder. Biotin-epoxomicin serves as an affinity reagent for identifying proteasomal catalytic subunits, and facilitates affinity purification of active proteasomal subunits for LC-MS identification. Biotin-epoxomicin can be used to study solid tumors derived from B16 melanoma .

HY-P11287A

DOTA-Pep-1L TFA	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research .

HY-P11306

Biotin-(Oaa)3-epoxomicin	Proteasome NF-κB	Inflammation/Immunology
Biotin-(Oaa)₃-epoxomicin is a biotin-labeled form of Epoxomicin (HY-13821), prepared by conjugating Epoxomicin with biotin via three hydrophilic oxaacetyl amino acid (Oaa) linkers. Biotin-(Oaa)₃-epoxomicin is primarily used in proteomic studies for the capture, identification and target validation of proteasome complexes, to determine the intracellular targets of epoxomicin. Epoxomicin acts as a proteasome inhibitor and NF-κB inhibitor, which effectively blocks inflammatory responses in mouse ear edema assays. It inhibits proteasome activity via covalent binding to catalytic subunits including LMP7, X, MECL1 and Z, with the strongest inhibitory effect on chymotrypsin-like activity, and does not interfere with non-proteasomal proteases such as trypsin and papain .

HY-163039

*DOTA-biotin*	Biochemical Assay Reagents	Inflammation/Immunology
DOTA-biotin is a DOTA-based small molecule hapten. DOTA-biotin has low tissue and whole-body retention in mice 4 h postinjection .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-P2336A

CCZ01048 TFA 3 Publications Verification	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10620

GGGYK-Biotin	Bacterial	Others
GGGYK-Biotin is a substrate peptide designed to study the substrate specificity of Sortase A. GGGYK-Biotin can be used to develop Sortase A variants with different substrate specificities .

HY-P3576A

Biotin-Gastrin Releasing Peptide, human TFA	Fluorescent Dye Bombesin Receptor	Neurological Disease Cancer
Biotin-Gastrin Releasing Peptide, human TFA is a biotinylated gastrin releasing peptide (GRP). Gastrin-releasing peptide (GRP) is a neuropeptide with growth-stimulatory and tumorigenic properties .

HY-P2546

Biotin-Substance P	Neurokinin Receptor	Neurological Disease
Biotin-Substance P is the biotin tagged Substance P. Substance P (Neurokinin P) is a neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R) .

HY-P10886

Zifogaptide	Gap Junction Protein Claudin	Inflammation/Immunology
Zifogaptide is a gap junction protein channel regulator. Zifogaptide mimics the PDZ-binding motif at the C-terminal of Claudin C and competitively interferes with the interaction between Claudin–TJP1 (ZO-1) scaffold. Zifogaptide can promote epithelial cell migration, reduce scar formation, and accelerate wound healing. Zifogaptide can be used for radiation dermatitis, skin injuries, etc .

HY-P5351A

*Hyaluronan-binding peptide, biotin* labeled TFA**	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Hyaluronan-binding peptide, biotin labeled TFA is a biological active peptide. (This peptide is a hyaluronan-binding peptide biotinylated through a C-terminal GGGSK linker. Hyaluronan (HA) is a nonsulfated glycosaminoglycan expressed in the extracellular matrix and on cell surfaces. HA plays a role in fertilization, embryonic development, wound healing, angiogenesis, leukocyte trafficking to inflamed tissues, and cancer metastasis. This peptide has been shown to block HA binding to CD44 receptors and inhibit T cell proliferation.) .

HY-P2491

*Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled*	Fluorescent Dye	Cardiovascular Disease Endocrinology
Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, one of three mammalian natriuretic peptides (NPs), has endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide has the potential for cardiovascular diseases research .

HY-P2136F

Biotin-COG1410 TFA	Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Biotin-COG1410 TFA is a biotin labled COG1410 (HY-P2136). COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease .

HY-P10273A

DOTA-Octreotide TFA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P11118A

Biotinylated CCDC61 peptide TFA CAPture peptide, biotin-CCDC61 (334-366) TFA	Biochemical Assay Reagents	Others
Biotinylated CCDC61 peptide (CAPture peptide, biotin-CCDC61 (334-366)) TFA is a biotinylated peptide derived from the centrosomal protein CCDC61. Biotinylated CCDC61 peptide TFA specifically isolates intact centrosomes .

HY-P11287

DOTA-Pep-1L	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research .

HY-P3844

Biotinyl-neuropeptide W-23 (human)	Transmembrane Glycoprotein Neuropeptide B/W Receptor	Neurological Disease
Biotinyl-neuropeptide W-23 (human) is a biotinylated Neuropeptide W-23 (human) (HY-P1035). Neuropeptide W-23 (human) is an agonist of NPBW1 (GPR7) and NPBW2 (GPR8) .

HY-P2549

Biotin-β-Amyloid (1-40)	Fluorescent Dye	Neurological Disease
Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-β-(1-40) peptide.

HY-P11026

DOTA-TMVP1446 DOTA-PEG4-TMVP1446	VEGFR	Cancer
DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with ⁶⁸Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-W038001

DOTA-benzene	Hapten	Cancer
DOTA-benzene is a DOTA-based small molecule hapten. DOTA-biotin has been used extensively as a hapten for PRIT .

HY-P2510

Parathyroid Hormone (1-34), human, biotinylated	Thyroid Hormone Receptor	Metabolic Disease
Parathyroid Hormone (1-34), human, biotinylated is a probe for the parathyroid hormone receptor, can be used for analyzing the interaction between parathyroid hormone and parathyroid hormone receptors in living cells and for purifying hormone-receptor complexes with affinity columns .

HY-P10307

DOTA-ubiquicidin (29–41)	Radionuclide-Drug Conjugates (RDCs) Bacterial	Infection
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ ⁶⁸Ga]Ga-DOTA-Ubiquicidin_29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10569

Biotin HER-2 substrate peptide	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

HY-13443F

*Exendin 4, biotin* labeled** Lys27(biotin)-Exendin 4	GCGR	Others
Exendin 4, biotin labeled is a biotin labeled Exendin 4 (HY-13443). Exendin 4 is a long-acting GLP-1 receptor agonist .

HY-P10951

(R)-Zadavotide guraxetan (R)-PSMA I&T; (R)-PNT-2002	PSMA	Cancer
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .

HY-P10273

DOTA-Octreotide	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P2551

Biotin-β-Amyloid (17-40)	Amyloid-β	Neurological Disease
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .

HY-P11118

Biotinylated CCDC61 peptide CAPture peptide, biotin-CCDC61 (334-366)	Biochemical Assay Reagents	Others
Biotinylated CCDC61 peptide (CAPture peptide, biotin-CCDC61 (334-366)) is a biotinylated peptide derived from the centrosomal protein CCDC61. Biotinylated CCDC61 peptide specifically isolates intact centrosomes .

HY-P2504

*Syk Kinase Peptide Substrate, Biotin* labeled**	Syk	Others
Syk Kinase Peptide Substrate, Biotin labeled is a biotin-labled Syk kinase peptide substrate.

HY-P3576

Biotin-Gastrin Releasing Peptide, human	Fluorescent Dye Bombesin Receptor	Neurological Disease Cancer
Biotin-Gastrin Releasing Peptide, human is a biotinylated gastrin releasing peptide (GRP). Gastrin-releasing peptide (GRP) is a neuropeptide with growth-stimulatory and tumorigenic properties .

HY-P10566

BCOR(498-514), biotinylated	BCL6	Cancer
BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an K_D value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells .

HY-P10372

pFYN peptide	Src	Cancer
pFYN peptide is a biotin-labled phosphorylated peptide substrate derived from FYN (a Src family kinase) .

HY-P11613

DOTA-WC8	EGFR	Cancer
DOTA-WC8 is a HER2-targeting peptide probe with a K_D of 61.20 nM. ⁶⁸Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research .

HY-P11461

Biotin-CRF, human, rat biotin-corticotropin releasing factor	Drug Derivative	Neurological Disease
Biotin-CRF, human, rat is a biotin-conjugated CRF (human, rat). CRF (human, rat) is a corticotropin-releasing hormone, paraventricular hypothalamic nucleus marker .

HY-P11553B

DOTA-ECL1i	Radionuclide-Drug Conjugates (RDCs) CCR	Cardiovascular Disease Inflammation/Immunology Cancer
DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with ⁶⁸Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer .

HY-P3335

SU015 DOTA-RGDfK dimer	Integrin Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
SU015 (DOTA-RGDfK dimer) is a Integrin α_vβ₅ and α_vβ₃ antagonist. SU015 exhibits comparable affinity for α_vβ₅ and α_vβ₃, with relatively higher potency and specificity compared to other integrins. SU015 inhibits α_vβ₃-mediated cell adhesion to fibrinogen, α_vβ₃-mediated adhesion of activated platelets to osteopontin, and α_vβ₅-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with ⁹⁰Y (i.e., RP697) or ¹⁷⁷Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors .

HY-P11769

RM2	CGRP Receptor	Cancer
RM2 is a GRPr antagonist. RM2 selectively binds to GRPr, blocks agonist-induced receptor internalization, and inhibits agonist-triggered intracellular calcium mobilization. RM2 can be used in studies related to prostate cancer .

HY-P11488

*JR11-PEG3-DOTA-PSMA-03*	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA	Cancer
JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC₅₀ s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ ⁶⁸Ga]. [ ⁶⁸Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .

Cat. No.	Product Name	Target	Research Area